TAK1 Expression is Associated with Increased PD-L1 and Decreased Cancer-specific Survival in Microsatellite-stable Colorectal Cancer

Overview

Journal Transl Oncol

Specialty Oncology

Date 2024 Jul 28

PMID 39068768

Authors

Norman J Galbraith

Jean A Quinn

Sara Sf Al-Badran

Kathryn A F Pennel

Lily V S Hillson

Phimmada Hatthakarnkul

Molly McKenzie

Noori Maka

Lynette Loi

Mikaela Frixou

Colin W Steele

Campbell S Roxburgh

Paul G Horgan

Donald C McMillan

Joanne Edwards

Affiliations

Soon will be listed here.

Abstract

Background: Transforming growth factor β-activated protein kinase-1 (TAK1) plays an important role in MAPK and NFκB pathways and has been associated with colorectal cancer. The aim of this study was to determine how cytoplasmic and juxtanuclear punctate staining of TAK1 relates to immune checkpoint expression and cancer specific survival in colorectal cancer.

Methods: Protein expression was assessed by immunohistochemistry on tissue microarrays from primary curative colorectal cancer resected specimens. Expression levels of cytoplasmic TAK1 by QuPath digital quantification and punctate TAK1 staining was scored using a manual point scoring technique and correlated with clinicopathological features, immune checkpoint expression and cancer-specific survival. Bulk RNA sequencing was performed in specimens to determine mutational profiles and differentially expressed genes.

Results: A cohort of 875 patients who had undergone colorectal cancer resection were assessed for TAK1 expression. Higher levels of cytoplasmic TAK1 expression correlated with elevated PD1 and PD-L1 expression (p < 0.010). High punctate TAK1 expression was more commonly identified in poorly differentiated colorectal cancers (p = 0.036), had dysregulated mutational and transcriptional profiles with decreased insulin-like growth factor 2(IGF2) expression (p < 0.010), and independently predicted poor cancer-specific survival (HR 2.690, 95% CI 1.419-5.100, p = 0.002). The association of punctate TAK1 expression and recurrence remained after subgroup analysis for microsatellite-stable colorectal cancer (p = 0.028).

Discussion: Punctate TAK1 expression is associated with worse cancer specific survival. TAK1 signalling may be an important pathway to investigate underlying mechanisms for recurrence in microsatellite-stable colorectal cancer.

References

Bernardino-Sgherri J, Siberchicot C, Auvre F, Busso D, Brocas C, El Masri G . Tumor resistance to radiotherapy is triggered by an ATM/TAK1-dependent-increased expression of the cellular prion protein. Oncogene. 2021; 40(19):3460-3469. DOI: 10.1038/s41388-021-01746-0. View

Takahashi H, Jin C, Rajabi H, Pitroda S, Alam M, Ahmad R . MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene. 2015; 34(40):5187-97. PMC: 4530107. DOI: 10.1038/onc.2014.442. View

Mukhopadhyay H, Lee N . Multifaceted roles of TAK1 signaling in cancer. Oncogene. 2019; 39(7):1402-1413. PMC: 7023988. DOI: 10.1038/s41388-019-1088-8. View

Wang Z, Jiang X, Li Q, Jin Y, Liu X, Wang F . Integrated analysis identifies low microRNA-215 expression as associated with a poor prognosis of patients with colorectal cancer through the IKβ-α signaling pathway. Transl Cancer Res. 2022; 9(9):5233-5244. PMC: 8798538. DOI: 10.21037/tcr-19-2424. View

Park J, Watt D, Roxburgh C, Horgan P, McMillan D . Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host. Ann Surg. 2015; 263(2):326-36. DOI: 10.1097/SLA.0000000000001122. View

Fu J, Xu Y, Yang Y, Liu Y, Ma L, Zhang Y . Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation. Sci Rep. 2019; 9(1):16937. PMC: 6858464. DOI: 10.1038/s41598-019-53276-1. View

Cui H, Cruz-Correa M, Giardiello F, Hutcheon D, Kafonek D, Brandenburg S . Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003; 299(5613):1753-5. DOI: 10.1126/science.1080902. View

Kang K, Min B, Ryu K, Kim K, Kyung Chang D, Kim J . The role of the CpG island methylator phenotype on survival outcome in colon cancer. Gut Liver. 2014; 9(2):202-7. PMC: 4351027. DOI: 10.5009/gnl13352. View

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218. PMC: 5073889. DOI: 10.1186/s13059-016-1070-5. View

10.

Barbie D, Tamayo P, Boehm J, Kim S, Moody S, Dunn I . Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009; 462(7269):108-12. PMC: 2783335. DOI: 10.1038/nature08460. View

11.

Gonzalez-Quezada B, Santana-Bejarano U, Corona-Rivera A, Pimentel-Gutierrez H, Silva-Cruz R, Ortega-de-la-Torre C . Expression profile of NF-κB regulated genes in sporadic colorectal cancer patients. Oncol Lett. 2018; 15(5):7344-7354. PMC: 5962836. DOI: 10.3892/ol.2018.8201. View

12.

Choo M, Kawasaki N, Singhirunnusorn P, Koizumi K, Sato S, Akira S . Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol Cancer Ther. 2006; 5(12):2970-6. DOI: 10.1158/1535-7163.MCT-06-0379. View

13.

Ma Q, Gu L, Liao S, Zheng Y, Zhang S, Cao Y . NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo. Apoptosis. 2018; 24(1-2):83-94. DOI: 10.1007/s10495-018-1498-z. View

14.

Quinn J, Bennett L, Patel M, Frixou M, Park J, Roseweir A . The relationship between members of the canonical NF-kB pathway, tumour microenvironment and cancer specific survival in colorectal cancer patients. Histol Histopathol. 2019; 35(6):569-578. DOI: 10.14670/HH-18-168. View

15.

Antonacopoulou A, Kottorou A, Dimitrakopoulos F, Marousi S, Kalofonou F, Koutras A . NF-κB2 and RELB offer prognostic information in colorectal cancer and NFKB2 rs7897947 represents a genetic risk factor for disease development. Transl Oncol. 2020; 14(1):100912. PMC: 7568186. DOI: 10.1016/j.tranon.2020.100912. View

16.

Siegel R, Miller K, Sauer A, Fedewa S, Butterly L, Anderson J . Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020; 70(3):145-164. DOI: 10.3322/caac.21601. View

17.

Zhou J, Zheng B, Ji J, Shen F, Min H, Liu B . LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo. Tumour Biol. 2014; 36(5):3301-8. DOI: 10.1007/s13277-014-2961-2. View

18.

Wu D, Wu P, Zhao L, Huang L, Zhang Z, Zhao S . NF-κB Expression and Outcomes in Solid Tumors: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015; 94(40):e1687. PMC: 4616757. DOI: 10.1097/MD.0000000000001687. View

19.

Totzke J, Gurbani D, Raphemot R, Hughes P, Bodoor K, Carlson D . Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chem Biol. 2017; 24(8):1029-1039.e7. PMC: 5576570. DOI: 10.1016/j.chembiol.2017.07.011. View

20.

Hatthakarnkul P, Ammar A, Pennel K, Officer-Jones L, Cusumano S, Quinn J . Protein expression of S100A2 reveals it association with patient prognosis and immune infiltration profile in colorectal cancer. J Cancer. 2023; 14(10):1837-1847. PMC: 10355195. DOI: 10.7150/jca.83910. View